📢 Our CEO Eduardo Bravo will be in London next week representing Citryll at the Jefferies London Healthcare Conference 2024, from 19-21 November. At this milestone 15th edition of Europe's largest healthcare conference, we look forward to connecting with industry leaders and sharing the progress of CIT-013, our innovative approach to treating immune-mediated inflammatory diseases. 📌Interested in meeting? We'd love to connect in London. Find out more about what we do at Citryll: https://citryll.com/ #JefferiesHealthcare #Citryll #Biotech #NETosis
Citryll’s Post
More Relevant Posts
-
Rare diseases need rare solutions. Think treating rare diseases is too complex? AnzuBridge is breaking barriers with next-generation solutions that enhance the efficacy of clinical trials for rare diseases. By integrating advanced data capture, analysis, and media review, AnzuBridge ensures every patient's data contributes to comprehensive insights and more effective treatments. Convinced yet? With precise and efficient evaluations, AnzuBridge's technology is not just innovative; it's a game-changer for those at the forefront of rare disease research. Ready to see how AnzuBridge can revolutionize your clinical trials? Contact us today to learn more and join the movement towards better treatment options for rare diseases. #clinicaltrials #clinicaltrialvideo #mediacapture #medtech #healthcare #medicaltechnology #clinicaltrialprofessionals #cro #clinicalresearch
-
🔬 Accepted Poster Presentation: Biomed Diagnostics at ASM Microbe 2024 Brandon Font, Research Scientist and Technical Services Manager at Biomed Diagnostics, a DCN Dx brand, will present Biomed's latest research with the Centers for Disease Control and Prevention (CDC) at ASM Microbe 2024. The study, "Extending Viability Time and Temperature Parameters for InPouch™ TV Trichomonas vaginalis Transportation," offers evidence supporting expanded time and temperature conditions for transporting T. vaginalis. These findings aim to provide healthcare providers and laboratories with data to consider more flexible logistical options, potentially enhancing diagnostic accuracy. 📍Read the press release here: https://hubs.ly/Q02wKMrd0 #ASMMicrobe2024 #BiomedDiagnostics #CDC #PublicHealth #ScientificResearch #Diagnostics #CultureDiagnostics #InfectiousDisease #SpecimenTransport
-
-
North America led the global celiac disease treatment market with a 41.8% revenue share in 2023, driven by increasing prevalence, growing awareness, the presence of major companies, and a robust medication supply chain. Detailed insights @ https://lnkd.in/dKvcpcXH Follow Grand View Research, Inc to gain further insights. #GVR #healthcare #medtech #healthtech #biotech #celiacdisease #celiac #celiacdiseaseawareness #CeliacDiseaseTreatment
-
-
Senior Partner at Deloitte | National Audit Leader - Japanese Services Group | Greater Tri-State Leader - Energy, Resources & Industrials | National Industrial Products & Construction Sub-Sector Leader - Trading Houses
Learn how #Biotech is elevating human health in therapeutic discovery and disease treatment—download Deloitte’s #xTech Futures report.
xTech Futures: Trends in biotechnology
-
Learn how #Biotech is elevating human health in therapeutic discovery and disease treatment—download Deloitte’s #xTech Futures report.
xTech Futures: Trends in biotechnology
-
Learn how #Biotech is elevating human health in therapeutic discovery and disease treatment—download Deloitte’s #xTech Futures report.
xTech Futures: Trends in biotechnology
-
Learn how #Biotech is elevating human health in therapeutic discovery and disease treatment—download Deloitte’s #xTech Futures report.
xTech Futures: Trends in biotechnology
-
Learn how #Biotech is elevating human health in therapeutic discovery and disease treatment—download Deloitte’s #xTech Futures report.
xTech Futures: Trends in biotechnology
-
Conducting clinical studies in rare diseases presents a unique set of challenges. Success can only be achieved if the burden on both sites and patients is minimized while ensuring reliable data collection. In this article, Juliet (Jules) Moritz, Senior Vice President, Strategic Solutions and Patient Centricity, ERGOMED Clinical Research, provides insight into why Ergomed is ideally positioned to design and conduct rare disease clinical trials with minimal unexpected difficulties. Find out how we ease the burden of Rare Disease research: https://lnkd.in/eMjBQFtU #RareDisease #ErgomedCRO #HealthcareInnovation #ClinicalResearch
-
